[Combination chemotherapy with @entity2879 , @entity1138 , and XXXX in advanced @entity1149 ].

@entity1 @entity1665 @entity13770 @entity137 @entity417 @entity1138 @entity1149 @entity786 @entity957 @entity2879 @entity152 @entity1431 @entity420 @entity1209
Forty-three @entity1 with advanced @entity1149 were treated with a combination chemotherapy regimen comprising @entity2879 100 mg/m2 p.o. days 1-5, @entity1138 10 mg/m2 i.v. day 1 and @entity786 500 mg/m2 i.v. day 1, every 4 weeks. The median age was 61, and the median initial @entity13770 . Fourteen @entity1 had received prior therapy. The response rates in previously untreated @entity1 were 25% (5/20) for @entity420 , 0% (0/4) for @entity957 , 0% (0/3) for @entity152 , and 18.5% (5/27) for all @entity1 . There were no responders among the pretreated @entity1 . The median survival time was 7 months for previously untreated @entity1 , 4 months for pretreated @entity1 and 6 months for all @entity1 . @entity1 with @entity420 survived significantly longer (8 months) than those with @entity957 (4 months) and @entity152 (3 months). @entity137 consisted of @entity1431 (74%), @entity417 (74%), @entity1209 (55%) and @entity1665 (94%).
